Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | GBP 354.52B | 33.8x | 1.3 | 8,030.87 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | GBP 236.26B | 59.7x | -3.5 | 14,288.80 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co Inc | London | Healthcare | Pharmaceuticals | GBP 196.56B | 20.7x | 0.13 | 7,760.80 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | GBP 191.98B | 20.4x | -6.18 | 22,841.71 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | GBP 191.98B | 20.4x | -6.14 | 24,057.92 | -10.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | GBP 162.52B | 11.9x | 0.14 | 8,120.21 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | GBP 155.31B | 30.4x | 7.22 | 10,000 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.2% Upside | Upgrade to Pro+ | |
Sanofi L | London | Healthcare | Pharmaceuticals | GBP 95.58B | 26.6x | -0.53 | 7,632.29 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | GBP 90.56B | 953.9x | -9.7 | 7,258.25 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | GBP 53.34B | 21.2x | -0.38 | 1,304.84 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.6% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | GBP 52.34B | 23.2x | -1.67 | 12,045.28 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | GBP 32.77B | 28.4x | -9.3 | 364.40 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.7% Upside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | GBP 26.72B | 133.5x | -5.31 | 14,033.38 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | GBP 18.98B | 14.9x | 1.55 | 13,127.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | GBP 16.73B | -22.8x | 0.1 | 1,704.68 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | GBP 15.16B | -2,379.2x | 24.31 | 3,582.94 | 41.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | GBP 8.78B | 25.2x | 1.96 | 4,291.06 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | GBP 7.71B | 30.7x | 2.4 | 2,239.44 | -5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | GBP 7.45B | 13.3x | 0.27 | 9,044.38 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | GBP 6.39B | 47.3x | 939.45 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Grifols Pref | London | Healthcare | Pharmaceuticals | GBP 6.39B | 47.3x | 769.23 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Orion Oyj | London | Healthcare | Pharmaceuticals | GBP 5.19B | 18.8x | 0.21 | 3,694.44 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
H Lundbeck L | London | Healthcare | Pharmaceuticals | GBP 4.79B | 15.9x | 3.6 | 501.12 | -74.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | GBP 4B | 46.7x | 0.49 | 1,812.70 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | GBP 4B | 17.7x | 0.2 | 1,804 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | GBP 4B | 9.3x | 0.04 | 2,200.03 | 113.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | GBP 2.87B | 39.7x | -5.08 | 20,804.54 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | GBP 2.49B | 127.4x | -3.11 | 4,246.84 | 13.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | GBP 2.33B | 19.9x | 1.08 | 28,024.96 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | GBP 2.23B | -69.1x | 8.16 | 261.02 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |